Glucosylifosfamide Mustard
Central Nervous System Neoplasm
Explore 48 assets in Central Nervous System Neoplasm →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00014300CT.gov Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Central Nervous System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Glucosylifosfamide Mustard (this asset) | European Organisation for Research and Treatment of Cancer - EORTC | P2 | B · 57 |
| Procarbazine | Universitätsmedizin Mannheim | P3 | BBB |
| Irinotecan | EpicentRx, Inc. | P2 | BBB |
| Vincristine Sulfate | Northwestern University | P3 | BBB |
| Etoposide | NewLink Genetics Corporation | P3 | BBB |
| Gefitinib | Memorial Sloan Kettering Cancer Center | P2 | BBB |
| Nivestim | St. Jude Children's Research Hospital | P3 | BBB |
| Isocyclophosphamide | Masonic Cancer Center, University of Minnesota | P3 | BBB |
| Camustine | Lisata Therapeutics, Inc. | P3 | BBB |
+42 more in the Central Nervous System Neoplasm cohort
Other indications for Glucosylifosfamide Mustard
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Neoplasm | — | P3 | B · 58 |
| Pancreatic Adenocarcinoma | — | P3 | B · 57 |
| Small Cell Lung Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Glucosylifosfamide Mustard in Central Nervous System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/glucosylifosfamide-mustard-central-nervous-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →